Scalper1 News
Heart-surgery giant Edwards Lifesciences (EW) rose more than 3% to an all-time high Monday morning after two analysts upgraded it in the wake of an acquisition. RBC Capital Markets’ Glenn Novarro raised his rating to outperform from sector perform, and set a price target of 185. Novarro wrote that Edwards’ $350 million acquisition of CardiAQ, announced after the close Friday, puts it in a leadership position in transcatheter mitral valve Scalper1 News
Scalper1 News